Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Phase II Study of Single Agent Lenvatinib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03168074
Recruitment Status : Recruiting
First Posted : May 30, 2017
Last Update Posted : June 16, 2017
Eisai Co., Ltd.
Tan Tock Seng Hospital
Information provided by (Responsible Party):
National University Hospital, Singapore